SCHEMBL335280

SCHEMBL335280

CCN(CC)Cc1cc(C(C)=O)ccc1O

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.97
JAK2 O60674 1/20 0.68
PKM P14618 1/20 0.64
HTT P42858 3/20 0.61
ALDH1A1 P00352 5/20 0.61
HIF1A Q16665 1/20 0.61
PRKCI P41743 1/20 0.59
KMT2A Q03164 3/20 0.58
KDM4E B2RXH2 2/20 0.58
MEN1 O00255 2/20 0.58
MAPT P10636 1/20 0.58
THRB P10828 1/20 0.58
APEX1 P27695 1/20 0.58
MAPK1 P28482 1/20 0.58
RECQL P46063 1/20 0.58
CACNA1B Q00975 1/20 0.58
APBA1 Q02410 1/20 0.58
MCL1 Q07820 1/20 0.58
HKDC1 Q2TB90 1/20 0.58
TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2482973 0.86 POLB (0.73) POLBJAK2PKMHTTALDH1A1
SCHEMBL2482978 0.86 POLB (0.73) POLBJAK2PKMHTTALDH1A1
SCHEMBL13338334 0.86 POLB (0.73) POLBJAK2PKMHTTALDH1A1
SCHEMBL1397612 0.85 POLB (0.71) POLBJAK2PKMHTTALDH1A1
SCHEMBL11620661 0.85 POLB (0.71) POLBJAK2PKMHTTALDH1A1
SCHEMBL385574 0.83 PKM (0.75) POLBJAK2PKMHTTALDH1A1
Hydrochloric Acid SCHEMBL11621347 0.83 POLB (0.74) POLBJAK2PKMHTTALDH1A1
SCHEMBL334398 0.82 ALDH1A1 (0.70) POLBPKMHTTALDH1A1HIF1A
SCHEMBL11619511 0.81 POLB (0.66) POLBJAK2PKMHTTALDH1A1
SCHEMBL2482865 0.81 JAK2 (1.00) POLBJAK2PKMHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 POLB 3348/4885JAK2 1547/4885PKM 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.